Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial

Authors

Yang Cao

Published

May 26, 2020

Abstract

Accumulating evidence proposed Janus-associated kinase (JAK) inhibitors as therapeutic targets warranting rapid investigation.

Supporters

Support the authors with ResearchCoin

Journal

Journal of Allergy and Clinical Immunology

Topics

DOI

10.1016/j.jaci.2020.05.019

License

other-oa

Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial

Authors

Yang Cao

Published

May 26, 2020

Abstract

Accumulating evidence proposed Janus-associated kinase (JAK) inhibitors as therapeutic targets warranting rapid investigation.

Supporters

Support the authors with ResearchCoin

Journal

Journal of Allergy and Clinical Immunology

Topics

DOI

10.1016/j.jaci.2020.05.019

License

other-oa

Paper

Paper

Paper

Paper

Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial

Abstract

Supporters

Journal

Topics

DOI

License

Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial

Abstract

Supporters

Journal

Topics

DOI

License

Supporters

Journal

Topics

DOI

License